RESUMO
OBJECTIVE: To study the prevalence and distribution of HBV genotypes in Spain for the period 2000-2016. METHODS: Retrospective study recruiting 2559 patients from 17 hospitals. Distribution of HBV genotypes, as well as sex, age, geographical origin, mode of transmission, HDV-, HIV- and/or HCV-coinfection, and treatment were recorded. RESULTS: 1924 chronically HBV native Spanish patients have been recruited. Median age was 54 years (IQR: 41-62), 69.6% male, 6.3% HIV-coinfected, 3.1% were HCV-coinfected, 1.7% HDV-co/superinfected. Genotype distribution was: 55.9% D, 33.5% A, 5.6% F, 0.8% G, and 1.9% other genotypes (E, B, H and C). HBV genotype A was closely associated with male sex, sexual transmission, and HIV-coinfection. In contrast, HBV genotype D was associated with female sex and vertical transmission. Different patterns of genotype distribution and diversity were found between different geographical regions. In addition, HBV epidemiological patterns are evolving in Spain, mainly because of immigration. Finally, similar overall rates of treatment success across all HBV genotypes were found. CONCLUSIONS: We present here the most recent data on molecular epidemiology of HBV in Spain (GEHEP010 Study). This study confirms that the HBV genotype distribution in Spain varies based on age, sex, origin, HIV-coinfection, geographical regions and epidemiological groups.
Assuntos
Coinfecção , Infecções por HIV , Hepatite B , Adulto , Coinfecção/epidemiologia , Feminino , Genótipo , Infecções por HIV/complicações , Infecções por HIV/epidemiologia , Hepatite B/epidemiologia , Vírus da Hepatite B/genética , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Espanha/epidemiologiaRESUMO
OBJETIVOS: En 1998 la Región de Europa de la Organización Mundial de la Salud fijó el objetivo de eliminar el sarampión. En este estudio se analizó la prevalencia de la inmunidad frente al virus del sarampión en la población del área sanitaria de Santiago de Compostela a partir de los datos obtenidos entre 2008-2018. PACIENTES Y MÉTODOS: Se estudiaron 7.150 pacientes diferentes que se dividieron en grupos según su año de nacimiento: 2010-2017, 2000-2009, 1990-1999, 1980-1989, 1953-1979 y <1953. La determinación en suero de IgG frente al virus del sarampión se realizó mediante un inmunoensayo quimioluminiscente comercializado. RESULTADOS: Se observó un mínimo (76%) para las tasas de protección frente al virus del sarampión en los nacidos entre 1990-1999. Por grupo de edad se vio que en todos los grupos las mujeres presentaron un porcentaje superior de anticuerpos frente al sarampión. En un modelo de regresión logística con año de nacimiento y sexo se obtuvo una odds ratio para el año de nacimiento (p < 0,001) de 1,06 y para el sexo (p = 0,0013) de 0,82. CONCLUSIONES: Se observaron seroprevalencias inferiores a partir de la implantación de la vacuna, un cambio más acusado durante el periodo de implantación y desde el plan de vacunación para el sarampión del año 2000 en Galicia, las tasas de protección frente al virus del sarampión han ido aumentado en nuestra área. Aunque se observó una mayor proporción de mujeres protegidas frente a la de hombres, estas diferencias fueron escasas
OBJECTIVES: In 1998, the Europe Region of the World Health Organization set the goal of eliminating measles. In this study, the prevalence of immunity against measles virus in the population of the health area of Santiago de Compostela was analyzed based on data obtained between 2008-2018. METHODS: A total of 7,150 different patients were studied and divided into groups according to their year of birth: 2010-2017, 2000-2009, 1990-1999, 1980-1989, 1953-1979 and <1953. The serum determination of IgG against measles virus was performed using a commercialized chemiluminescent immunoassay. RESULTS: A minimum (76%) was observed for measles virus protection rates in those born between 1990-1999. By age group it was seen that in all groups the women presented a higher percentage of antibodies against measles. In a logistic regression model with year of birth and sex, an odds ratio of 1.06 (p < 0.001) was obtained for the year of birth and of 0.82 (p = 0.0013) for sex. CONCLUSIONS: It was observed lower seroprevalences from the implantation of the vaccine and a more pronounced change during the implantation period. From the vaccination plan for measles of the year 2000 in Galicia, the rates of protection against the virus of the measles have been increasing in our area. Although there is a greater proportion of women protected against men, these differences are small
Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Anticorpos Antivirais/sangue , Imunoglobulina G/sangue , Sarampo/imunologia , Vírus do Sarampo/imunologia , Fatores Etários , Estudos Transversais , Modelos Logísticos , Razão de Chances , Estudos Soroepidemiológicos , EspanhaRESUMO
INTRODUCCIÓN: Presentamos el mayor estudio realizado en Galicia sobre prevalencia y distribución de genotipos/subtipos del VHC. MÉTODOS: Estudio retrospectivo recopilando al total de pacientes crónicamente infectados por VHC entre el 1 de enero del 2000 y el 31 de diciembre del 2015 en 3 de las principales áreas sanitarias: Santiago, Pontevedra y Vigo. Recogimos datos sobre prevalencia y distribución de genotipos/subtipos, vías de transmisión, género, edad y coinfección con VIH/VHB. RESULTADOS: Reclutamos a 4.469 pacientes, con una mediana de edad 50 años (RIC 57-45), el 72,3% hombres, el 0,4% coinfectado con otro genotipo, el 20,6% coinfectado con VIH y un 35,2% con VHB. Transmisión parenteral (83,1%), desconocida (15,3%), sexual (1,4%) y vertical (0,2%). Distribución de genotipos: 62,9% VHC-1 (29,2% VHC-1a y 31,9% VHC-1b), 3,4% VHC-2, 21,0% VHC-3, 12,6% VHC-4 y 0,1% VHC-5. CONCLUSIÓN: La distribución de genotipos muestra diferencias significativas respecto a la observada en España. Dicha distribución varía con la edad, el género, la coinfección con VIH o VHB, y dentro de áreas geográficas
INTRODUCTION: We present the largest study conducted in Galicia on the prevalence and distribution of HCV genotypes/subtypes. METHODS: Retrospective study collecting the total number of patients chronically infected by HCV between 2000.01.01 to 2015.12.31 in 3 of the main health areas: Santiago, Pontevedra and Vigo. RESULTS: We collected a total of 4469 patients. The median age was 50 years (IQR 57-45), 72,3% were men, 0,4% were coinfected with another genotype, 20,6% were coinfected with HIV and 35.2% with HBV. The main route of transmission was parenteral (83,1%), followed by unknown (15,3%), sexual (1,4%) and vertical (0,2%). The distribution of genotypes was: 62,9% HCV-1 (29,2% HCV-1a and 31,9% HCV-1b), 3,4% HCV-2, 21,0% HCV-3, 12,6% HCV-4 and 0,1% HCV-5. CONCLUSION: The distribution of genotypes in Galicia shows significant differences with respect to that observed in Spain. This distribution varies with age, gender, coinfection with HIV and/or HBV, and within geographical areas
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Hepacivirus/genética , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/virologia , Genótipo , Hepacivirus/classificação , Estudos Retrospectivos , Espanha/epidemiologia , Fatores de TempoRESUMO
INTRODUCTION: We present the largest study conducted in Galicia on the prevalence and distribution of HCV genotypes/subtypes. METHODS: Retrospective study collecting the total number of patients chronically infected by HCV between 2000.01.01 to 2015.12.31 in 3of the main health areas: Santiago, Pontevedra and Vigo. RESULTS: We collected a total of 4469 patients. The median age was 50 years (IQR 57-45), 72,3% were men, 0,4% were coinfected with another genotype, 20,6% were coinfected with HIV and 35.2% with HBV. The main route of transmission was parenteral (83,1%), followed by unknown (15,3%), sexual (1,4%) and vertical (0,2%). The distribution of genotypes was: 62,9% HCV-1 (29,2% HCV-1a and 31,9% HCV-1b), 3,4% HCV-2, 21,0% HCV-3, 12,6% HCV-4 and 0,1% HCV-5. CONCLUSION: The distribution of genotypes in Galicia shows significant differences with respect to that observed in Spain. This distribution varies with age, gender, coinfection with HIV and/or HBV, and within geographical areas.
Assuntos
Hepacivirus/genética , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/virologia , Feminino , Genótipo , Hepacivirus/classificação , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Espanha/epidemiologia , Fatores de TempoRESUMO
No disponible
Assuntos
Humanos , Masculino , Feminino , Criança , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Grupo Borrelia Burgdorferi/patogenicidade , Doença de Lyme/diagnóstico , Doença de Lyme/sangue , Doença de Lyme/tratamento farmacológico , EspanhaRESUMO
Introducción. La edad y sexo a la que se produce la primoinfección por VEB en España es un tema poco estudiado. El objetivo de este trabajo es conocer su relación con la presencia de la primoinfección por VEB entre los años 2006 a 2015 en nuestra área sanitaria. Pacientes y métodos. Se estudiaron 578 pacientes del área sanitaria de Santiago de Compostela con patrones serológicos de primoinfección por VEB, resultados serológicos de IgM-VCA positivo, IgG-VCA positivo y EBNA negativo correspondientes a los años 2006 a 2015. Resultados. Se encontraron 260/578 (45%) adolescentes (11-19 años). En número de casos por edad se observaron dos máximos, a los 2 y 16 años. Entre los 14-19 años, un 62% (79/127) de mujeres tenían entre 14-16 años, mediana de edad 15,8 años (IQ: 14,8-16,4) frente a un 48% (49/102) de hombres, mediana de edad 16 años (IQ: 15,7-16,6) (p=0,032, p=0,02, respectivamente). Conclusiones. Como en nuestro estudio, en los países desarrollados la mayoría de primoinfecciones por VEB ocurren en la adolescencia y se observa una distribución bimodal en relación a la edad. Durante la adolescencia las mujeres adquieren antes que los hombres la primoinfección por VEB (AU)
Introduction. In Spain, the age and sex to which the primary infection by EBV is produced is poorly studied. The objective of this work is to know its relation with the presence of the primary infection by EBV between the years 2006 and 2015 in our health area. Patients and methods. From the Santiago de Compostela health area between 2006 and 2015, 578 patients with serological patterns of EBV primoinfection were selected. This patients presented serological results of IgM-VCA positive, IgG-VCA positive and EBNA negative. Results. We found 260/578 (45%) adolescents (11- 19 years). In the number of cases by age the maximum was observed, at 2 and 16 years. Between 14-19 years, 62% (79/127) of women between 14-16 years of age, median age 15.8 years (IQ: 14.8-16.4) compared to 48% (49/102) of men, median age 16 years (IQ: 15.7-16.6) (p = 0.032, p = 0.02, respectively). Conclusions. As in our study, in the developed countries the majority of primary infections by EBV occur in adolescence and a bimodal distribution is observed in relation to age. During adolescence women acquire before men the first infection by EBV (AU)
Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Herpesvirus Humano 4/isolamento & purificação , Infecções por Vírus Epstein-Barr/epidemiologia , Mononucleose Infecciosa/epidemiologia , Distribuição por Idade e Sexo , Estudos RetrospectivosRESUMO
No disponible
